Vertex Pharmaceuticals (VRTX) Q4 Earnings: What To Expect

Vertex Pharmaceuticals (VRTX) Q4 Earnings: What To Expect

Anthony Lee

Wed, February 11, 2026 at 12:03 PM GMT+9 2 min read

In this article:

VRTX

-1.57%

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Thursday afternoon. Here’s what you need to know.

Vertex Pharmaceuticals met analysts’ revenue expectations last quarter, reporting revenues of $3.08 billion, up 11% year on year. It was a mixed quarter for the company, with a beat of analysts’ EPS estimates but full-year revenue guidance meeting analysts’ expectations.

Is Vertex Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Vertex Pharmaceuticals’s revenue to grow 8.4% year on year to $3.16 billion, slowing from the 15.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $5.15 per share.

Vertex Pharmaceuticals Total Revenue

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Vertex Pharmaceuticals has missed Wall Street’s revenue estimates twice over the last two years.

Looking at Vertex Pharmaceuticals’s peers in the therapeutics segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Biogen’s revenues decreased 7.1% year on year, beating analysts’ expectations by 3.6%, and Amgen reported revenues up 8.6%, topping estimates by 4.1%. Biogen traded up 4.6% following the results while Amgen was also up 8.2%.

Read our full analysis of Biogen’s results here and Amgen’s results here.

Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the therapeutics stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.7% on average over the last month. Vertex Pharmaceuticals is up 1.1% during the same time and is heading into earnings with an average analyst price target of $514.32 (compared to the current share price of $464.10).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.

Terms and Privacy Policy

Privacy Dashboard

More Info